AGIOS PHARMACEUTICALS, INC.
AGIO· Nasdaq· Pharmaceutical Preparations
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- -698.3%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- –
We record prices for the companies we cover; AGIO is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 58.0M
- Revenue
- $54.0M
- Free cash flow
- -$377.3M
- Owner earnings
- -$429.8M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- -873.9%
- Net
- -764.0%
- Free cash flow
- -698.3%
- Owner earnings
- -795.6%
- Stock pay
- 97.3%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- -34.6%
- ROE, 5 yr avg
- 13.8%
Growth (CAGR)
- Revenue, 3 yr
- 56.0%
- Revenue, 5 yr
- –
- Revenue, 9 yr
- -2.8%
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 9 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 9 yr
- –
Financial health · FY2025
- Cash and investments
- $854.4M
- Total debt
- –
- Net cash
- –
- Debt/Equity
- –
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- -3.4%
Financials: ten years from the 10-Ks
Revenue
$54.0M
-2.8% a year over 9 years
FY2016FY2025
Margins
Operating-873.9%Net-764.0%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow-$377.3MOwner earnings-$429.8M
FY2025
FY2016FY2025
Diluted shares
58.0M
-3.4% over 9 years, net buybacks
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | $69.9M | $43.0M | $94.4M | $117.9M | $0 | $0 | $14.2M | $26.8M | $36.5M | $54.0M |
| Revenue growth | 18.2% | -38.5% | 119.4% | 24.9% | -100.0% | – | – | 88.4% | 36.1% | 48.0% |
| Gross margin | – | – | – | – | – | – | – | – | – | – |
| Operating margin | -287.6% | -745.8% | -384.0% | -268.2% | – | – | -2732.1% | -1459.5% | -1166.5% | -873.9% |
| Net income | -$198.5M | -$314.7M | -$346.0M | -$411.5M | -$327.4M | $1.6B | -$231.8M | -$352.1M | $673.7M | -$412.8M |
| Net margin | -284.0% | -731.6% | -366.6% | -349.0% | – | – | -1627.8% | -1312.6% | 1845.9% | -764.0% |
| Diluted EPS | – | – | – | $-6.86 | $-4.74 | $26.55 | $-4.23 | $-6.33 | $11.64 | $-7.12 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – | – |
| Cash | ||||||||||
| Operating cash flow | $38.6M | -$285.2M | -$304.4M | -$370.6M | -$290.8M | -$407.3M | -$309.5M | -$296.1M | -$389.8M | -$373.0M |
| Capital expenditure | $9.9M | $4.6M | $7.0M | $12.0M | $14.1M | $5.7M | $4.9M | $999.0K | $1.7M | $4.3M |
| Free cash flow | $28.6M | -$289.9M | -$311.4M | -$382.6M | -$304.9M | -$413.1M | -$314.4M | -$297.1M | -$391.5M | -$377.3M |
| Stock-based compensation | $42.1M | $47.8M | $73.4M | $58.0M | $61.6M | $53.5M | $49.3M | $44.8M | $42.8M | $52.6M |
| Owner earnings? | -$13.4M | -$337.7M | -$384.8M | -$440.7M | -$366.5M | -$466.6M | -$363.7M | -$341.8M | -$434.4M | -$429.8M |
| Free cash flow per share | – | – | – | $-6.38 | $-4.42 | $-6.83 | $-5.74 | $-5.34 | $-6.76 | $-6.51 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – | – | – | – |
| Diluted shares | – | – | – | 60.0M | 69.0M | 60.4M | 54.8M | 55.7M | 57.9M | 58.0M |
| Share count change? | – | – | – | – | 15.0% | -12.4% | -9.4% | 1.6% | 4.0% | 0.1% |
| Balance sheet | ||||||||||
| Cash and equivalents | $160.8M | $102.7M | $70.5M | $80.9M | $127.4M | $203.1M | $139.3M | $88.2M | $76.2M | $89.1M |
| Short-term investments | $380.6M | – | $514.8M | $483.9M | $445.5M | $816.9M | $643.9M | $688.7M | $817.5M | $765.3M |
| Total debt | – | – | – | – | – | – | – | – | – | – |
| Net debt | – | – | – | – | – | – | – | – | – | – |
| Shareholders' equity | $358.6M | $375.5M | $687.5M | $640.5M | $399.5M | $1.3B | $1.1B | $811.0M | $1.5B | $1.2B |
Latest filings
| 2026-07-30 | 10-Q | Quarterly report |
| 2026-07-30 | 8-K | Earnings release |
| 2026-04-29 | 10-Q | Quarterly report |
| 2026-04-29 | 8-K | Earnings release |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-02-12 | 10-K | Annual report |
| 2026-02-12 | 8-K | Earnings release |
| 2025-10-30 | 10-Q | Quarterly report |
| 2025-10-30 | 8-K | Earnings release |
| 2025-07-31 | 10-Q | Quarterly report |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
